Yeah, I think it's a bit early for institutional. But, there could be some interest after FDA. Getting into a stock before institutional interest was one of the reasons why I liked BIEL. I'm not crazy about management, but believe the products have real potential. There will be a push for alternative pain therapies, BIEL can play a key role in this marketplace if they have the management to execute.
News 
Market Data 
Discover 
